Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Paul Kirkegaard"'
Autor:
Patrick Sand, MSc, Traci Aladeen, BA, Paul Kirkegaard, BS, Dennis LaChance, BS, Christine Slover, PharmD
Publikováno v:
Current Therapeutic Research, Vol 77, Iss C, Pp 99-104 (2015)
Background: VIBATIV is a once-daily, injectable lipoglycopeptide antibiotic approved in the U.S. for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus
Externí odkaz:
https://doaj.org/article/44814e93e10b498b8f902482574a9b47
Autor:
Paul Kirkegaard
Publikováno v:
The Journal of the American Dental Association. 154:459
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cc6914e3dfb3e0fb847b4b5c15ec4be
https://doi.org/10.1016/j.adaj.2023.04.008
https://doi.org/10.1016/j.adaj.2023.04.008
Autor:
Paul Kirkegaard
Publikováno v:
The Journal of the American Dental Association. 152:501
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2c6d1d6a80f01435236ba44705ba3a5
https://doi.org/10.1016/j.adaj.2021.05.010
https://doi.org/10.1016/j.adaj.2021.05.010
Publikováno v:
Current Therapeutic Research, Clinical and Experimental
Current Therapeutic Research, Vol 77, Iss C, Pp 99-104 (2015)
Current Therapeutic Research, Vol 77, Iss C, Pp 99-104 (2015)
Background VIBATIV is a once-daily, injectable lipoglycopeptide antibiotic approved in the U.S. for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4f3f6d57c096b7609adbfe17682cdb
Autor:
Paul Kirkegaard
Publikováno v:
The Journal of the American Dental Association. 151:384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0db868f2c6e81c23592bffa8cc177aab
https://doi.org/10.1016/j.adaj.2020.04.018
https://doi.org/10.1016/j.adaj.2020.04.018